Proceedings of the National Academy of Sciences · 2019 · 161 citations · 41 references
MedicineOncologyPharmacologyBiophotonicsCancer PharmacologyDrug DeliveryCancer NanomedicineNanomedicineNanoparticle DesignPhotodynamic TherapyRadiation TherapyTheranostic NanoparticlesCancer NanotherapyCancer Photodynamic TherapyMolecular TargetingPhotodynamic Therapy NanomaterialsPhotosensitizersSinglet Oxygen FormationTumor SelectivityTumor-targeting Peptides
Photodynamic therapy (PDT), a treatment that uses a photosensitizer, molecular oxygen, and light to kill target cells, is a promising cancer treatment method. However, a limitation of PDT is its dependence on light that is not highly penetrating, precluding the treatment of tumors located deep in the body. Copper-cysteamine nanoparticles are a new type of photosensitizer that can generate cytotoxic singlet oxygen molecules upon activation by X-rays. In this paper, we report on the use of copper-cysteamine nanoparticles, designed to be targeted to tumors, for X-ray-induced PDT. In an in vivo study, results show a statistically significant reduction in tumor size under X-ray activation of pH-low insertion peptide-conjugated, copper-cysteamine nanoparticles in mouse tumors. This work confirms the effectiveness of copper-cysteamine nanoparticles as a photosensitizer when activated by radiation and suggests that these Cu-Cy nanoparticles may be good candidates for PDT in deeply seated tumors when combined with X-rays and conjugated to a tumor-targeting molecule.
41
Photosensitizers in clinical PDT
Ron R. Allison, Gordon Downie, Rosa Cuenca et al. · Photodiagnosis and Photodynamic Therapy · 2004 · 1K citations
Chao Wang, Huiquan Tao, Liang Cheng et al. · Biomaterials · 2011 · 818 citations
Engineering, Oncology, Pharmacology +16
Continuous growth of mean tumor diameter in a subset of grade II gliomas
Emmanuel Mandonnet, Jean‐Yves Delattre, Marie‐Laure Tanguy et al. · Annals of Neurology · 2003 · 485 citations · Full text